Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,199 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RAYOS Clear all
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

NCT02758132
View directory record Official record
Conditions
Prostate Cancer
Interventions
Denosumab, Enzalutamide, Abiraterone, Prednisone
Biological · Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT00507416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

NCT03834506
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 20, 2026, 9:50 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions
Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
36
States / cities
Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

NCT02462252
View directory record Official record
Conditions
Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions
BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 4 Interventional Results available

Reduction in Symptomatic Esophageal Stricture Formation

NCT02039115
View directory record Official record
Conditions
Esophageal Stenosis
Interventions
prednisone, placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Withdrawn Phase 4 Interventional

Corticosteroids Therapy and Pneumocystis Jirovecii Pneumonia (PCP)

NCT00636935
View directory record Official record
Conditions
Pneumocystis Carinii Pneumonia
Interventions
Antibiotics only, Antibiotics + Corticosteroids, Corticosteroids + antibiotics
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Suspended Phase 2 Interventional

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

NCT06738368
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
Drug · Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
Interventions
DA-EPOCH, Rituximab, CHOP, Acalabrutinib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

NCT01691508
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, OCS (prednisone/prednisolone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

NCT00224874
View directory record Official record
Conditions
Graft vs Host Disease, Immune System Disorders
Interventions
Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, Pentostatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Duarte, California • San Diego, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 20, 2026, 9:50 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT07287397
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

NCT01051570
View directory record Official record
Conditions
Prostate Cancer
Interventions
carboplatin, RAD 001, prednisone, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Evanston, Illinois • Detroit, Michigan • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

NCT00459186
View directory record Official record
Conditions
Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer
Interventions
RAD001, Docetaxel, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
5
States / cities
Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

NCT01994850
View directory record Official record
Conditions
CD30 Positive Primary Mediastinal Large B-cell Lymphoma, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30-Positive Gray Zone Lymphoma
Interventions
brentuximab vedotin
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Belatacept to Prevent Organ Rejection in Kidney Transplant Patients

NCT00346151
View directory record Official record
Conditions
Renal Transplant
Interventions
Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma

NCT02285062
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
lenalidomide, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 80 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Fayetteville, Arkansas • Orange, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis

NCT00262405
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
zileuton, azathioprine/prednisone
Drug
Lead sponsor
University of Michigan
Other
Eligibility
35 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 3 Interventional

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

NCT00187005
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase, L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 20, 2026, 9:50 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

NCT00996502
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Bevacizumab, Erlotinib, Prednisone
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 20, 2026, 9:50 AM EDT
Completed Phase 1 Interventional

Pazopanib, Docetaxel, Prednisone Prostate

NCT01385228
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 20, 2026, 9:50 AM EDT